Calcineurin-inhibitor minimization protocols in heart transplantation

Transplant International

Volumn 22, Issue 1, 2009, Pages 78-89

  Zuckermann, Andreas Oliver ^a   Aliabadi, Arezu Z ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Cardiac transplantation; Immunosuppression; Minimization; Mycophenolate mofetil; Rapamycin; Renal dysfunction

Indexed keywords

AZATHIOPRINE; BASILIXIMAB; CALCINEURIN INHIBITOR; CYCLOSPORIN A; DACLIZUMAB; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EVEROLIMUS; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY;

ABSENCE OF SIDE EFFECTS; ACNE; ACUTE GRAFT REJECTION; CHRONIC KIDNEY DISEASE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDEMA; GASTROINTESTINAL DISEASE; HEART TRANSPLANTATION; HEPATITIS B; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INTERSTITIAL PNEUMONIA; KIDNEY FAILURE; LOW DRUG DOSE; MOUTH ULCER; MULTICENTER STUDY; NEPHROTOXICITY; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; PROTEINURIA; PYREXIA IDIOPATHICA; RANDOMIZED CONTROLLED TRIAL; RENAL PROTECTION; REVIEW; SKIN DISEASE; SURVIVAL RATE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

CALCINEURIN; CLINICAL TRIALS AS TOPIC; DRUG ADMINISTRATION SCHEDULE; GRAFT REJECTION; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FAILURE, CHRONIC; MYCOPHENOLIC ACID; SIROLIMUS;

EID: 57349197312     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2008.00771.x     Document Type: Review

References (72)

1. John R, Rajasinghe HA, Chen JM, Weinberg AD, et al. Long-term outcomes after cardiac transplantation: an experience based on different eras of immunosuppressive therapy. Ann Thorac Surg 2001 72 : 440.
2. Taylor DO, Edwards LB, Boucek MM, et al. International Society for Heart and Lung Transplantation. Registry of the International Society for Heart and Lung Transplantation: twenty-third official adult heart transplantation report-2006. J Heart Lung Transplant 2006 25 : 869.
3. Bloom RD, Doyle AM. Kidney disease after heart and lung transplantation. Am J Transplant 2006 6 : 671.
4. Ojo AO, Held PJ, Port FK, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003 349 : 931.
5. Alam A, Badovinac K, Ivis F, Trpeski L, Cantarovich M. The outcome of heart transplant recipients following the development of end-stage renal disease: analysis of the Canadian Organ Replacement Register (CORR). Am J Transplant 2007 7 : 461.
6. Senechal M, Dorent R, du Montcel ST, et al. End-stage renal failure and cardiac mortality after heart transplantation. Clin Transplant 2004 18 : 1.
7. Hunt S, Stinson E, Oyer P, et al. Results of immunoconversion from cyclosporine to azathioprine in heart transplant recipients with progressive nephrotoxicity. Transplant Proc 1987 19 : 2522.
8. Kobashigawa J, Miller L, Renlund D, et al. A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Mycophenolate Mofetil Investigators. Transplantation 1998 66 : 507.
9. Keogh A, Richardson M, Ruygrok P, et al. Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years: a randomized clinical trial. Circulation 2004 110 : 2694.
10. Eisen HJ, Tuzcu EM, Dorent R, et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 2003 349 : 847.
11. Kobashigawa JA, Miller LW, Russell SD, et al. Tacrolimus with mycophenolate mofetil (MMF) or sirolimus vs. cyclosporine with MMF in cardiac transplant patients: 1-year report. Am J Transplant 2006 6 : 1377.
12. Rosenberg PB, Vriesendorp AE, Drazner MH, et al. Induction therapy with basiliximab allows delayed initiation of cyclosporine and preserves renal function after cardiac transplantation. J Heart Lung Transplant 2005 24 : 1327.
13. Cantarovich M, Giannetti N, Barkun J, Cecere R. Antithymocyte globulin induction allows a prolonged delay in the initiation of cyclosporine in heart transplant patients with postoperative renal dysfunction. Transplantation 2004 78 : 779.
14. Delgado DH, Miriuka SG, Cusimano RJ, Feindel C, Rao V, Ross HJ. Use of basiliximab and cyclosporine in heart transplant patients with pre-operative renal dysfunction. J Heart Lung Transplant 2005 24 : 166.
15. Larson TS, Dean PG, Stegall MD, et al. Complete avoidance of calcineurin inhibitors in renal transplantation: a randomized trial comparing sirolimus and tacrolimus. Am J Transplant 2006 6 : 514.
16. Webster AC, Lee VWS, Chapman JR, Craig JC. Target of rapamycin inhibitors (sirolimus, and everolimus) for primary immunosuppression of kidney transplant recipients: a systematic review and meta-analysis of randomized trials. Transplantation 2006 81 : 1234.
17. Ekberg H, Tedesco-Silva H, Demirbas A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007 357 : 2562.
18. Meiser B, Reichart B, Adamidis I, Uberfuhr P, Kaczmarek I. First experience with de novo calcineurin-inhibitor-free immunosuppression following cardiac transplantation. Am J Transplant 2005 1 : 827.
19. Vazquez de Prada JA, Vilchez FG, Cobo M, et al. Sirolimus in de novo heart transplant recipients with severe renal impairment. Transpl Int 2006 19 : 245.
20. Hershberger RE, Starling RC, Eisen HJ, et al. Daclizumab to prevent rejection after cardiac transplantation. N Engl J Med 2005 352 : 2705.
21. Mehra MR, Zucker MJ, Wagoner L, et al. A multicenter, prospective, randomized, double-blind trial of basiliximab in heart transplantation. J Heart Lung Transplant 2005 24 : 1297.
22. Cantarovich M, Metrakos P, Giannetti N, Cecere R, Barkun J, Tchervenkov J. Anti-CD25 monoclonal antibody coverage allows for calcineurin inhibitor "holiday" in solid organ transplant patients with acute renal dysfunction. Transplantation 2002 73 : 1169.
23. Potter B, Giannetti N, Cecere R, Cantarovich M. Long-term calcineurin inhibitor "holiday" using daclizumab in a heart transplant patient with acute renal dysfunction. J Heart Lung Transplant 2005 24 : 1126.
24. Cantarovich M. Renal protective strategies in heart transplant patients. Curr Opin Cardiol 2007 22 : 133.
25. Aleksic I, Baryalei M, Busch T, et al. Improvement of impaired renal function in heart transplant recipients treated with mycophenolate mofetil and low-dose cyclosporine. Transplantation 2000 69 : 1586.
26. Tedoriya T, Keogh AM, Kusano K, et al. Reversal of chronic cyclosporine nephrotoxicity after heart transplantation-potential role of mycophenolate mofetil. J Heart Lung Transplant 2002 21 : 976.
27. Baryalei M, Zenker D, Pieske B, Tondo K, Dalichau H, Aleksic I. Renal function and safety of heart transplant recipients switched to mycophenolate mofetil and low-dose cyclosporine. Transplant Proc 2003 35 : 1539.
28. Zuckermann A, Ploner M, Keziban U, et al. Benefit of mycophenolate- mofetil (MMF) in patients with cyclosporine (CYA) induced nephropathy after cardiac transplantation. J Heart Lung Transplant 2001 20 : 163.
29. Sanchez V, Delgado JF, Morales JM, et al. Chronic cyclosporine-induced nephrotoxiciy in heart transplant patients: long-term benefits of treatment with mycophenolate mofetil and low-dose cyclosporine. Transplant Proc 2004 36 : 2823.
30. Boyer O, Le Bidois J, Dechaux M, Gubler MC, Niaudet P. Improvement of renal function in pediatric heart transplant recipients treated with low-dose calcineurin inhibitor and mycophenolate mofetil. Transplantation 2005 79 : 1405.
31. Manito N, Kaplinsky EJ, Roca J, et al. Heart transplant recipient clinical profile improvement following mycophenolate mofetil late incorporation into the treatment schedule. Clin Transplant 2005 19 : 304.
32. Al-Aly Z, Sachdeva A, Philoctete Ashley JM, Bastani B. Preliminary experience with mycophenolate mofetil for preservation of renal function in cardiac transplant patients with documented cyclosporine nephrotoxicity. Nephrology 2006 11 : 151.
33. Angermann CE, Störk S, Costard-Jäckle A, et al. Reduction of cyclosporine after introduction of mycophenolate mofetil improves chronic renal dysfunction in heart transplant recipients - the IMPROVED multi-centre study. Eur Heart J 2004 25 : 1626.
34. Hamour IM, Lyster HS, Burke MM, Rose ML, Banner NR. Mycophenolate mofetil may allow cyclosporine and steroid sparing in de novo heart transplant patients. Transplantation 2007 83 : 570.
35. Meiser B, Kaczmarek I, Mueller M, et al. Low-dose tacrolimus/sirolimus and steroid withdrawal in heart recipients is highly efficacious. J Heart Lung Transplant 2007 26 : 598.
36. Lehmkuhl HB, Mai D, Dandel M, et al. Observational study with everolimus (Certican) in combination with low-dose cyclosporine in de novo heart transplant recipients. J Heart Lung Transplant 2007 26 : 700.
37. Trösch F, Rothenburger M, Schneider M, et al. First experience with rapamycin-based immunosuppression to improve kidney function after heart transplantation. Thorac Cardiovasc Surg 2004 52 : 163.
38. Schweiger M, Wasler A, Prenner G, et al. Everolimus and reduced cyclosporine trough levels in maintenance heart transplant recipients. Transpl Immunol 2006 16 : 46.
39. Balfour IC, Srun SW, Wood EG, Belsha CW, Marshall DL, Ferdman BR. Early renal benefit of rapamycin combined with reduced calcineurin inhibitor dose in pediatric heart transplantation patients. J Heart Lung Transplant 2006 25 : 518.
40. Ross H, Pflugfelder P, Haddad H, et al. Cyclosporine reduction in the presence of everolimus: 3-month data from a Canadian pilot study of maintenance cardiac allograft recipients. J Heart Lung Transplant 2008 27 : 197.
41. Lehmkuhl H, Ross H, Eisen H, Valantine H. Everolimus (certican) in heart transplantation: optimizing renal function through minimizing cyclosporine exposure. Transplant Proc 2005 37 : 4145.
42. Zuckermann A, Manito N, Epailly E, et al. Multidisciplinary insights on clinical guidance for the use of proliferation signal inhibitors in heart transplantation. J Heart Lung Transplant 2008 27 : 141.
43. Rothenburger M, Zuckermann A, Bara C, et al. Recommendations for the use of everolimus (Certican) in heart transplantation: results from the second German-Austrian Certican Consensus Conference. J Heart Lung Transplant 2007 26 : 305.
44. Cantarovich M, Elstein E, de Varennes B, Barkun JS. Clinical benefit of neoral dose monitoring with cyclosporine 2-hr post-dose levels compared with trough levels in stable heart transplant patients. Transplantation 1999 68 : 1839.
45. Cantarovich M, Besner JG, Barkun JS, Elstein E, Loertscher R. Two-hour cyclosporine level determination is the appropriate tool to monitor Neoral therapy. Clin Transplant 1998 12 : 243.
46. Kittleson M, Skye A, Felker G, et al. De novo C2 monitoring immediately after cardiac transplantation is not associated with improved renal function. J Heart Lung Transplant 2006 25 : S127.
47. Cantarovich M, Giannetti N, Cecere R. Impact of cyclosporine 2-h level and mycophenolate mofetil dose on clinical outcomes in de novo heart transplant patients receiving anti-thymocyte globulin induction. Clin Transplant 2003 17 : 144.
48. Barnard JB, Thekkudan J, Richardson S, et al. Cyclosporine profiling with C2 and C0 monitoring improves outcomes after heart transplantation. J Heart Lung Transplant 2006 25 : 564.
49. Cantarovich M, Ross H, Arizón JM, et al. Benefit of neoral C2 monitoring in de novo cardiac transplant recipients receiving basiliximab induction. Transplantation 2008 85 : 992.
50. Keogh A, Wang SS, Zuckermann A, et al. Everolimus in de novo heart transplant recipients six month data on cyclosporine reduction and impact on renal function. J Heart Lung Transplant 2007 26 : S202.
51. Cantarovich M, Elstein E, de Varennes B, Barkun JS. Clinical benefit of neoral dose monitoring with cyclosporine 2-hr post-dose levels compared with trough levels in stable heart transplant patients. Transplantation 1999 68 : 1839.
52. Mathias HC, Ozalp F, Will MB, et al. A randomized, controlled trial of C0- Vs C2-guided therapeutic drug monitoring of cyclosporine in stable heart transplant patients. J Heart Lung Transplant 2005 24 : 2137.
53. Hunt J, Bedánová H, Starling RC, et al. Premature Termination of a Prospective, Open Label, Randomized, Multicenter Study of Srl to Replace CNIs (CNI) in a Standard Care Regimen of CNI, MMF and Corticosteroids Early after Heart Transplantation. J Heart Lung Transplant 2007 26 (2S S203.
54. Snell GI, Levvey BJ, Chin W, et al. Sirolimus allows renal recovery in lung and heart transplant recipients with chronic renal impairment. J Heart Lung Transplant 2002 21 : 540.
55. Groetzner J, Meiser B, Landwehr P, et al. Mycophenolate mofetil and sirolimus as calcineurin inhibitor-free immunosuppression for late cardiac-transplant recipients with chronic renal failure. Transplantation 2004 77 : 568.
56. Zakliczynski M, Nozynski J, Zakliczynska H, Rozentryt P, Zembala M. Deterioration of renal function after replacement of cyclosporine with sirolimus in five patients with severe renal impairment late after heart transplantation. Transplant Proc 2003 35 : 2331.
57. Lyster H, Panicker G, Leaver N, Banner NR. Initial experience with sirolimus and mycophenolate mofetil for renal rescue from cyclosporine nephrotoxicity after heart transplantation. Transplant Proc 2004 36 : 3167.
58. Bestetti RB, Theodoropoulos TA, Burdmann EA, Santos MA, Abbud-Filho M. Switch from cyclosporine to sirolimus as a treatment of acute renal failure complicating cardiogenic shock in a heart transplant recipient. Int J Cardiol 2006 112 : 83.
59. Fernandez-Valls M, Gonzalez-Vilchez F, de Prada JA, Ruano J, Ruisanchez C, Martin-Duran R. Sirolimus as an alternative to anticalcineurin therapy in heart transplantation: experience of a single center. Transplant Proc 2005 37 : 4021.
60. De Meester JM, Van Vlem B, Walravens M, et al. Preservation of renal function after heart transplantation: initial single-center experience with sirolimus. Transplant Proc 2005 37 : 1835.
61. Aranda-Dios A, Lage E, Sobrino JM, et al. Sirolimus experience in heart transplantation. Transplant Proc 2006 38 : 2547.
62. Cabezón S, Lage E, Hinojosa R, Ordóñez A, Campos A. Sirolimus improves renal function in cardiac transplantation. Transplant Proc 2005 37 : 1546.
63. Moro J, Almenar L, Martinez-Dolz L, et al. mTor Inhibitors and their secondary effects in cardiac transplant recipients: a descriptive study. Transplant Proc 2007 39 : 2365.
64. Kushwaha SS, Khalpey Z, Frantz RP, et al. Sirolimus in cardiac transplantation: use as a primary immunosuppressant in calcineurin inhibitor-induced nephrotoxicity. J Heart Lung Transplant 2005 24 : 2129.
65. Hunt J, Lerman M, Magee MJ, Dewey TM, Herbert M, Mack MJ. Improvement of renal dysfunction by conversion from calcineurin inhibitors to sirolimus after heart transplantation. J Heart Lung Transplant 2005 24 : 1863.
66. Gleissner CA, Doesch A, Ehlermann P, et al. Cyclosporine withdrawal improves renal function in heart transplant patients on reduced-dose cyclosporine therapy. Am J Transplant 2006 6 : 2750.
67. Rothenburger M, Teerling E, Bruch C, et al. Calcineurin inhibitor-free immunosuppression using everolimus (Certican) in maintenance heart transplant recipients: 6 months' follow-up. J Heart Lung Transplant 2007 26 : 250.
68. Gustafsson F, Ross HJ, Delgado MS, Bernabeo G, Delgado DH. Sirolimus-based immunosuppression after cardiac transplantation: predictors of recovery from calcineurin inhibitor-induced renal dysfunction. J Heart Lung Transplant 2007 26 : 998.
69. Raichlin E, Khalpey Z, Kremers W, et al. Replacement of calcineurin-inhibitors with sirolimus as primary immunosuppression in stable cardiac transplant recipients. Transplantation 2007 84 : 467.
70. Aliabadi AZ, Pohanka E, Seebacher G, et al. Development of proteinuria after switch to sirolimus-based immunosuppression in long-term cardiac transplant patients. Am J Transplant 2008 8 : 854.
71. Mancini D, Pinney S, Burkhoff D, et al. Use of rapamycin slows progression of cardiac transplantation vasculopathy. Circulation 2003 108 : 48.
72. Raichlin E, Bae JH, Khalpey Z, et al. Conversion to sirolimus as primary immunosuppression attenuates the progression of allograft vasculopathy after cardiac transplantation. Circulation 2007 116 : 2726.